The model simulation will enable maintenance doses to be given more accurately for future study.Ĭlinical Trial Registration: identifier: NCT01970072 Total clearance was 1.49 L min −1, central volume was 2.1 L, inter-compartmental clearances were 0.96 and 0.27 L min −1, respectively. A three-compartment model best described HR7056 pharmacokinetics. Up to 63 subjects were evaluated, using Bispectral Index (BIS) and Modified Observer's Assessment of Alertness/Sedation (MOAA/S) as pharmacodynamics endpoints. We report on modeling of the data and simulations of dosage regimens for future study. To avoid inadequate anesthesia and predict return of cognition, allowing for immediate neurological evaluation, HR7056 pharmacokinetics and pharmacodynamics were characterized in Chinese healthy subjects. HR7056 is a new benzodiazepine, showing more faster acting onset and recovery than currently available short-acting sedatives. 4Clinical Trial Center, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.3Department of Anesthesiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.2Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Ying Zhou 1,2 *, Pei Hu 1, Yuguang Huang 3, Nuoer Sang 3, Kaicheng Song 3, Hongyun Wang 1, Jinhua Wen 2, Ji Jiang 1 * and Xia Chen 1,4 *